NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

人工心臟瓣膜市場 - 預測(2021年∼2026年)

Prosthetic Heart Valve Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023178
出版日期 內容資訊 英文 113 Pages
商品交期: 最快1-2個工作天內
價格
人工心臟瓣膜市場 - 預測(2021年∼2026年) Prosthetic Heart Valve Market - Forecasts from 2021 to 2026
出版日期: 2021年07月12日內容資訊: 英文 113 Pages
簡介

全球人工心臟瓣膜的市場規模,預計從2019年的56億5,700萬美元,2026年達到94億8,700萬美元,在預期期間中以7.67%的年複合成長率成長。

隨著心臟瓣膜症與其他心血管疾病增加,心臟瓣膜的採用增加,促進市場成長。再加上投藥和治療的技術進步,診斷,治療,及可利用的替代手段相關患者的意識高漲,市場前景提高。再加上政府的放鬆管制的醫療基礎設施整備,也大幅推動預期期間中的市場發展。可是,醫療費的急劇上升和併發症的可能性將成為市場規模的限制。

本報告提供全球人工心臟瓣膜市場調查,市場趨勢和阻礙因素,各類型、用戶、地區的市場分析,競爭企業和情形等相關資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供給企業的交易
    • 購買企業的交易
    • 替代品的威脅
    • 新加入業者的威脅
    • 產業的競爭企業間的競爭關係
  • 產業的價值鏈分析

第5章 各類型:人工心臟瓣膜市場

  • 簡介
  • 人工心臟瓣膜
  • 組織心臟瓣膜

第6章 用戶:各人工心臟瓣膜市場

  • 簡介
  • 醫院和診所
  • 研究所
  • 其他

第7章 各地區:人工心臟瓣膜市場

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 日本
    • 其他

第8章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業與市場收益
  • 合併,收購,協定,共同研究
  • 供應商競爭力 矩陣

第9章 企業簡介

  • Boston Scientific Corporation
  • Edward Lifesceinces Corporation
  • Abbott
  • Medtronic
  • JenaValve Technology Inc.
  • Corcym S.r.l. (LinaNova PLC)
  • CyroLife Inc.
目錄
Product Code: KSI061610596

The prosthetic heart valve market is projected to grow at a CAGR of 7.67% during the forecast period to reach US$9.487 billion by 2026, from US$5.657 billion in 2019. Prosthetic heart valves are an artificial valve that is implanted in the human heart in place of valves that are improperly functioning or are not functioning at all. These valves are either damaged or disease-ridden and hinder the functioning of the heart, causing health issues or risk of loss of life.

Rising cases of valvular heart diseases coupled with other cardiovascular diseases are leading to a rise in the adoption of heart valves, and hence driving the market growth. Furthermore, technological advancement in medication and treatment has increased awareness among patients regarding the diagnosis, treatments, and alternatives available, increasing the market prospects. Moreover, favorable government regulation resulting in better healthcare infrastructure will considerably encourage market development during the forecasted period. However, surging medical expenses and chances of complications will constrain the market size.

This report segments the prosthetic heart market based on type, user, and geography. By type, the market is segmented as mechanical heart valves and tissue heart valves. By user, the prosthetic heart valve market is distinguished as hospitals and clinics, research and laboratories, and others.

Mechanical heart valves have better market standing and are projected to hold a dominating share in the prosthetic heart valve industry.

By type, the mechanical heart valve is estimated to hold a dominating share during the forecasted period. Mechanical heart valves are carbon-based and have the capability of lasting a patient's lifetime. These valves are made from carbon leaflets which result in excellent blood flow performance. However, mechanical heart valves suffer from the abounding requirements for blood thinner therapy, which will last the patients' lifetime, reducing bleeding and clotting.

Tissue heart valves, on the other hand, are harvested from pigs' or cow's hearts. The tissues collected are treated and neutralized for better body adaption. However, this biological formation of the heart valve is equally prone to disease and has limited reliability. The tissues wear out after some time and require replacement. Moreover, these valves are less suitable for patients above 65 years of age.

Data from a study conducted by CyroLife Inc. shows that the cumulative survival chances, after 15 years, are greater for a person with a mechanical heart valve than with a biological or tissue heart valve. While the study finds that tissue heart valves are effective in patients aged 40 to 49 years, mechanical heart valves are reliable in patients age 50 or above. However, the probability of death is lower in the case of patients with mechanical heart valves than those with tissue valves in both categories of age group. Observing the greater and fruitful results of mechanical valves, it is hence anticipated that these valves will dominate the market during the forecasted period, increasing their market share with rising innovation in the industry.

Geographical Outlook.

The report on prosthetic heart valves also covers detailed regional analysis, dividing the market into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific region. The North American region is predicted to have a significant share of the market. Rising instances of cardiovascular diseases in the regions, especially in the US, will drive the industry's growth. Heart diseases are a leading cause of death in the US, causing 1 in every 4 deaths in the country. Citing data from the Centers for Disease Control and Prevention (CDC), about 665,000 Americans die due to heart diseases in the US, which makes 1 person death every 36 seconds. The rising instances of cardiovascular diseases have raised concerns and government attention. Million Hearts is an initiative undertaken by the US government aiming to prevent more than 1 million heart-linked deaths and strokes within 5 years. It is estimated that prosthetic heart valves will have a significant role in fulfilling the aim, increasing the industry prospects.

The Asia Pacific region showcases robust growth potential with rising health awareness and government expenditure on improving health infrastructure. The Union Budget of 2020-21 in India saw a surge in spending on the healthcare sector, from 1.5% of GDP in the previous year to 1.8% of GDP in the budget. This allocation for the healthcare sector further increased by 10% in the budget for 2021-22. Increasing expenditure will drive the market for prosthetic heart valves significantly.

Key Developments.

In June 2021, Corcym S.r.l acquired LivaNova heart valve business to expand its portfolio of heart disease solutions. Through this acquisition, Crocym aims to enter the market for heart care and increase its market share in the industry.

Covid-19 Impact on Prosthetic Heart Valve Market.

The coronavirus pandemic says a surge in cases of cardiovascular and heart diseases. A report by the American College of Cardiology states that from January to June 2020, 397.042 cardiovascular linked deaths occurred in the US. However, a significant fall in demand for prosthetic heart valves was observed as patients reduced hospital visits, checkups, and operations owing to fear of getting infected.

Market Segmentation:

  • By Type
  • Mechanical Heart Valve
  • Tissue Heart Valve
  • By End-User
  • Hospitals and Clinics
  • Research Laboratories
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. The threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. Prosthetic Heart Valve Market, by Type

  • 5.1. Introduction
  • 5.2. Mechanical Heart Valve
  • 5.3. Tissue Heart Valve

6. Prosthetic Heart Valve Market, by Users

  • 6.1. Introduction
  • 6.2. Hospital and Clinics
  • 6.3. Research Laboratories
  • 6.4. Others

7. Prosthetic Heart Valve Market, by Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. The Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. South Korea
    • 7.6.4. Taiwan
    • 7.6.5. Thailand
    • 7.6.6. Indonesia
    • 7.6.7. Japan
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrative
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Boston Scientific Corporation
  • 9.2. Edward Lifesceinces Corporation
  • 9.3. Abbott
  • 9.4. Medtronic
  • 9.5. JenaValve Technology Inc.
  • 9.6. Corcym S.r.l. (LinaNova PLC)
  • 9.7. CyroLife Inc.